This is an aggregated industry headline. Read the full story at BioPharma Dive →
Viridian may have edge over Amgen in eye drug showdown, analysts argue
The FDA, through a new approval, gave Viridian's drug a label that some on Wall Street believe makes it well-positioned to compete against Tepezza in the thyroid eye disease market.
By BioPharma Dive
· Jun 30, 2026
· via BioPharma Dive
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Tara Sparks was just days away from starting her new job at Novo Nordisk in February 2025 when she gathered wi…
The WeekFierceBiotech ↗
QuantumCell has licensed AlzeCure Pharma's Alzheimer's disease platform and lead asset for $12 million upfront…
The WeekBriefing
FDA approved Orca Bio’s Tregzi, the first allogeneic regulatory T cell therapy for blood cancer patients needi…